Research articles
ScienceAsia 47 (2021):ID 143-152 |doi:
10.2306/scienceasia1513-1874.2021.017
RHEB methylation in white blood cell, a novel
candidate marker for breast cancer screening
Sutasinee Asayuta,b,+, Charoenchai Puttipanyalearsc,d,+, Prakasit Rattanatanyongc,d,
Somchai Thanasitthichaie, Nakarin Kitkumthornf,*, Apiwat Mutirangurac,d,*
ABSTRACT: Aberrant DNA methylation of tumor surrounding stromal cells is one of epigenetic changes, partly caused
by the secretion of tumor cells. Here, we searched the tumor-induced DNA methylation profile in white blood cells
(WBCs) caused by the secretion of breast cancer cell, that will be possible marker for breast cancer screening. Using
DNA methylation microarray, we identified aberrant DNA methylated genes from co-culture model between healthy
controls peripheral blood mononuclear cells (PBMCs) with 3 breast cancer cell lines. From bioinformatics analysis, six
methylated CpG sites in 3 validation genes were selected for preliminary test to determine the most effective CpG sites
for detection in breast cancer patient WBCs using methylation-specific polymerase chain reaction (MSP). After test, the
cg03998173 of RHEB was selected as a validation gene with the result of 100% sensitivity and 80% specificity. Later,
this methylation marker determined in the WBCs from 200 breast cancer patients and 200 healthy controls by SYBR
green-based real-time MSP (RT-MSP). The RHEB methylation were detected in WBCs from 188 (94%) breast cancer
patients and 59 (29.50%) healthy controls with high sensitivity of 94% and specificity of 70.50% (P-value < 0.0001).
In conclusion, tumor-induced DNA methylation in WBCs caused by the secretion of breast cancer cells can be effective
tumor marker for breast cancer screening. The RHEB methylation is a new highly sensitive and specific tumor marker
from DNA methylation change in white blood cells of breast cancer patient blood. Therefore, the RHEB methylation
may be considered as a tumor marker for breast cancer screening.
Download PDF
154 Downloads 1365 Views
| a |
Program of Medical Science, Faculty of Medicine, Chulalongkorn University, Bangkok 10330 Thailand |
| b |
Research Division, National Cancer Institute, Bangkok 10400 Thailand |
| c |
Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok 10330 Thailand |
| d |
Center of Excellence in Molecular Genetics of Cancer and Human Diseases, Department of Anatomy,
Faculty of Medicine, Chulalongkorn University, Bangkok 10330 Thailand |
| e |
Institute of Medical Research and Technology Assessment, Department of Medical Services, Ministry of
Public Health, Nonthaburi 11000 Thailand |
| f |
Department of Oral Biology, Faculty of Dentistry, Mahidol University, Bangkok 10400 Thailand |
* Corresponding author, E-mail: mapiwat@chula.ac.th, nakarinkit@gmail.com
Received 22 Oct 2020, Accepted 11 Dec 2020
|
